Fig. 2: CD4+ T cells improved the migration of CD4−CIK cells through IFN-γ/CXCL9,10,11/CXCR3.
From: CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
A Illustration of chemotaxis assay of CD4−CIK cells toward supernatants derived from mixed tumor co-cultures. B Quantification of CD4−CIK cell migration in the tumor-conditioned medium in the presence or absence of CD4+ T cells. C Flow cytometric quantification of CD4−CIK migration in the tumor-conditioned medium before and after transmigration. D Quantification of chemokine-related mRNA expression in tumor cells and macrophages (left); flow cytometric analysis of IFN-γ expression in supernatants from tumor-conditioned medium (right). E Quantification of chemokine-related mRNA expression in tumor cells and macrophages in the presence of IFN-γ or anti-IFN-γ. F Quantification of CD4-CIK cell migration in tumor (A549 or H520)-conditioned medium in the presence of different neutralizing antibodies, IFN-γ or CD4+ T cells at 24 h. G Schematic diagram depicting the dosing schedule and timing for a subcutaneous transplantation tumor model. H, I Subcutaneous growth of tumor cells (A549) in each group of mice (n = 5) treated with PBS, CD4-CIK cells, CIK cells, and CIK + AMG487. J Flow cytometric examination of the number of CD3+CD8+ T cells infiltration in tumor. K Specific imaging of immunohistochemistry from CIK + AMG487 and CIK groups, scale bars: 100 µm. Error bars indicate SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (one-way ANOVA or Student's t test).
